Obesity and unhealthy diets trigger a variety of health problems, including type 2 Diabetes with more than 60,000,000 Europeans suffering from it. Pharmaceutical companies have long been seeking for therapeutic interventions to protect from the health problems associated with the metabolic syndrome. A team led by Richard Moriggl from the Ludwig Boltzmann Institute for Cancer Research has now discovered a molecular mechanism that might be suitable as target for such a therapy.
The Ludwig Boltzmann Society (LBI Trauma) is partner in a just started 2020 Health EC project within regenerative medicine (PHC 16 call) 2016-2019.
The project “Arrest Blindness” deals with Eye Cornea Regeneration/Replacement by tissue engineering technology. This project was one of 6 (out of 312 applications) which were funded. Of such new therapies about 200.000 patients/year (Europe only) could benefit.
Vienna, 2nd of November 2014 - A new 23 million euro initiative to accelerate the search for an effective HIV vaccine begins today.
Financed by the European Commission, the European AIDS Vaccine Initiative (EAVI2020) brings together leading HIV researchers from public organisations and biotech companies from across Europe, Australia, Canada and the USA in a focused effort to develop protective and therapeutic HIV vaccines.
On the 20th of October the LBG presented two new Ludwig Boltzmann Institutes (LBI). Both LBI are the result of the fourth call for proposals for the formation of new institutes.
The following scientists were able to convince the international experts of their research programme during the ambitious peer review process: Dr. Kaan Boztug, LBI for Rare and Undiagnosed Diseases and Dr. Markus Mitterhauser, LBI for Applied Diagnostics.
We wish both directors and their teams best of luck for their future work!
The community of “Tell us!” has taken a decision: Psychotropic drugs, mental resilience and health care structures are the three most important issues for future research in the field of mental health.
Under www.redensiemit.org , all those with an interest have until 13 October to vote on the future research of mental illness as of the Ludwig Boltzmann Gesellschaft's 'Tell us!' initiative
Vienna, 29 September 2015 - When is a mental illness considered cured? In what form does media consumption influence mental health? What can be done to keep the symptoms that arise after discontinuation of psychotropic drugs from leading to misdiagnoses? To date, all of these questions have been inadequately addressed by the current research on mental illness. From more than 400 contributions submitted by patients, therapists and doctors, experts at the 'Tell us!' open innovation initiative have identified proposals for future research questions for which all interested parties may cast their votes online between today and 13 October, under www.redensiemit.org.
Prof. Heinz Redl, Ph.D., Director of the LBI for Experimental and Clinical Research, has been elected as a fellow (FTERM) of the Tissue Engineering and Regenerative Medicine International Society (TERMIS). The society has more than 4.000 members worldwide and had the international meeting 2012 in Vienna.
Vienna, 22.7.2015 - A gene that is responsible for cancer growth plays a totally unexpected role in prostate cancer. The gene Stat3 is controlled by the immune modulator interleukin 6 and normally supports the growth of cancer cells. The international research team led by Prof. Lukas Kenner from the Medical University of Vienna, the University of Veterinary Medicine Vienna, and the Ludwig Boltzmann Institiute for Cancer Research (LBI-CR) discovered a missing link for an essential role of Stat3 and IL-6 signalling in prostate cancer progression.
This March the Ludwig Boltzmann Institute for Social Science History has co-organised a Workshop at the Trinity College Dublin. The Podcasts of "The 'Languages of War' Workshop" are now available online!
The Lab for Open Innovation in Science, LOIS, is the first education programme in which scientists can learn how to apply Open Innovation methods and principles along the entire process of generating and disseminating new scientific knowledge.
LOIS addresses researchers and scientists from Universities, Universities of Applied Sciences and other (non-profit) research organizations.